Vasoactive intestinal peptide binding autoantibodies in autoimmune humans and mice.

Bangale Y, Cavill D, Gordon T, Planque S, Taguchi H, Bhatia G, Nishiyama Y, Arnett F, Paul S

Peptides1 Dec 2002Cited by 15 (Europe PMC)

PMID12535706DOI10.1016/s0196-9781(02)00265-6PepBankPUB-12535706

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone8

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

01HumanNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneObservational studyOther
VIP-binding autoantibodies were readily detected in humans without autoimmune disease.
In plain wordsAntibodies that bind VIP were easy to find in people without autoimmune disease.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicableVIP-binding autoantibodies in humans without autoimmune disease
Study
n: not reported in source
Outcome group
Immune response · Immune and inflammation
Source sentences
Summary
but they were readily detected in humans without autoimmune disease.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-1253570603
02HumanNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneObservational studyOther
VIP binding activity was increased in patients with systemic lupus erythematosus.
In plain wordsIn people with lupus, more antibody binding to VIP was linked to the disease.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseVIP binding activity in systemic lupus erythematosus
Study
n: not reported in source
Outcome group
Immune response · Immune and inflammation
Source sentences
Summary
Increased VIP binding activity was evident in patients with systemic lupus erythematosus
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-1253570605
03HumanNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneObservational studyOther
VIP binding activity was not increased in patients with systemic sclerosis, Sjögren's syndrome, rheumatoid arthritis or autoimmune thyroiditis.
In plain wordsIn people with systemic sclerosis, Sjögren's syndrome, rheumatoid arthritis or autoimmune thyroiditis, antibody binding to VIP was not higher.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changeVIP binding activity in other autoimmune diseases
Study
n: not reported in source
Outcome group
Immune response · Immune and inflammation
Source sentences
Summary
Increased VIP binding activity was evident in patients with systemic lupus erythematosus but not systemic sclerosis, Sjögren's syndrome (SS), rheumatoid arthritis or autoimmune thyroiditis.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-1253570606
04AnimalNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneAnimal study (in vivo)Other
In autoimmune-prone MRL/lpr mice, autoantibodies that bind VIP were detected in serum.
In plain wordsIn autoimmune-prone mice, antibodies against the body's own VIP were found in blood.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicableVIP-binding autoantibodies in MRL/lpr mouse sera
Study
mousen: not reported in source
MRL/lpr mice prone to autoimmune disease
Outcome group
Immune response · Immune and inflammation
Source sentences
Summary
Autoantibodies capable of binding the immunoregulatory neuropeptide vasoactive intestinal peptide (VIP) were detected in the sera of a mouse strain prone to autoimmune disease due to the lpr mutation (MRL/lpr).
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-1253570601
05AnimalNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneAnimal study (in vivo)Other
VIP-binding autoantibodies were not present in control wildtype mice.
In plain wordsIn control mice, antibodies against the body's own VIP were not found.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changeVIP-binding autoantibodies in control wildtype mice
Study
mousen: not reported in source
Control wildtype MRL mice
Outcome group
Immune response · Immune and inflammation
Source sentences
Summary
The autoantibodies were not present in control wildtype MRL/lpr mice
1 context sentence(design, population, supporting numbers)
Summary · context
Autoantibodies capable of binding the immunoregulatory neuropeptide vasoactive intestinal peptide (VIP) were detected in the sera of a mouse strain prone to autoimmune disease due to the lpr mutation (MRL/lpr).
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-1253570602
06LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneEx vivo tissueOther
The VIP binding by autoantibodies was due to low-affinity recognition of VIP.
In plain wordsIn lab tests, antibodies bound VIP only weakly.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicableAffinity of VIP binding by autoantibodies
Study
n: not reported in source
Outcome group
Immune response · Immune and inflammation
Source sentences
Summary
The binding was due to low affinity VIP recognition.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-1253570604
07LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cell-free)Other
From a phage display library of lupus patients, one Fv clone with VIP-selective binding and several clones cross-reactive with unrelated peptides were identified.
In plain wordsIn lab tests, one antibody fragment from a lupus library bound VIP selectively, and several bound unrelated peptides too.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicableVIP-selective Fv clone from lupus patient phage display library
Study
humann: not reported in source
Outcome group
Immune response · Immune and inflammation
Source sentences
Summary
One Fv clone displaying VIP-selective binding and several clones displaying cross-reactivity with unrelated peptides were identified.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-1253570607
08LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cell-free)Mechanism
In the VIP-selective Fv clone from lupus patients, replacement mutations were preferentially located in the complementarity determining regions that contact the antigen.
In plain wordsIn lab tests, changes in the VIP-selective antibody fragment clustered in the regions that contact its target.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicableLocation of replacement mutations in the VIP-selective Fv clone
Study
humann: not reported in source
Outcome group
Immune response · Immune and inflammation
Source sentences
Summary
Replacement mutations in the VIP-selective clone were preferentially localized in the regions known to make contacts with the antigen, i.e. the complementarity determining regions, suggesting that the selective binding activity is due to immunological maturation of the antibodies.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-1253570608

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 12:41 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.